Medicinal composition for treating diabetes, and its application

A diabetes drug and composition technology, applied in the field of diabetes treatment drugs, can solve the problems of stimulating the digestive tract, effective dose difference, anorexia, etc., and achieve the effect of improving the use effect, reducing risk, and reducing the concentration of the drug

Inactive Publication Date: 2013-08-28
NANJING MEDICAL UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, metformin hydrochloride also has some disadvantages: stimulating the digestive tract, causing anorexia, nausea, abdominal pain, diarrhea, etc., and lactic acidosis may occur if taken in large quantities
Due to the large difference in the effective doses of metformin and glycine for lowering blood sugar, when the molar ratio of metformin and glycine is 1:1, no synergistic effect can be produced

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating diabetes, and its application
  • Medicinal composition for treating diabetes, and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Preparation of diabetic mouse model

[0026] Streptozotocin (STZ) can damage pancreatic islet cells, resulting in insufficient insulin secretion and hyperglycemia, leading to type 1 diabetes. We used the method of intraperitoneal injection of STZ (50mg / kg) to establish a type Ⅰ diabetes model, selected 8-week-old male C57 mice, injected STZ intraperitoneally for five consecutive days, and tested blood glucose one week later. The mice with blood glucose greater than 11.1mmol / L were returned to For the diabetes group (Wld(S) protects against peripheral neuropathy and retinopathy in an experimental model of diabetes in mice. Diabetologia. 2011,54(9):2440-50.) The diabetic mouse model was prepared for subsequent experiments.

[0027]

Embodiment 2

[0028] Example 2 Glycine and metformin compound synergy experiment

[0029] The experiment was divided into five groups: negative control group (normal mice + normal saline), model group (STZ + normal saline), metformin hydrochloride group (STZ + Metformin 150mg / kg), glycine group (STZ + Glycine 600mg / kg), glycine And metformin compound group (STZ+Metformin150mg / kg +Glycine600mg / kg), intraperitoneal injection of drugs for a week, detection of changes in blood sugar:

[0030] Administration method: intraperitoneal injection of drug for one week;

[0031] Detection index: take it as the main index, and observe the clinical manifestations of animals at the same time.

[0032] The effect of each prescription on the blood sugar of diabetic mice is shown in figure 1 . After one-way analysis of variance by LSD method, the results showed that there were statistical differences among the groups (p<0.05). Compared with the model group, glycine and metformin hydrochloride compound...

Embodiment 3

[0034] Example 3 Compound synergy experiment of different ratios of glycine and metformin

[0035] The experiment was divided into five groups: negative control group (normal mice + normal saline), model group (group I, STZ + normal saline), glycine and metformin compound 1:2 group (group II, STZ + Metformin100mg / kg + Glycine200mg / kg ), glycine and metformin compound 1:3 group (group III, STZ+Metformin100mg / kg +Glycine300mg / kg), glycine and metformin compound 1:4 group (group IV, STZ+Metformin100mg / kg+Glycine400mg / kg), intraperitoneal injection Drugs for a week, detect changes in blood sugar:

[0036] Administration method: intraperitoneal injection of drug for one week;

[0037] Detection index: take it as the main index, and observe the clinical manifestations of animals at the same time.

[0038] The effect of each prescription on the blood sugar of diabetic mice is shown in figure 2 . Compared with the model group, both the glycine and metformin hydrochloride compou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicinal composition for treating diabetes, and its application in the preparation of medicines for treating the diabetes. The medicinal composition comprises glycine and metformin hydrochloride, and the best mass ratio of glycine to metformin hydrochloride is 3:1, 4:1 or 5:1. The cooperation of glycine and metformin hydrochloride realizes a reinforced effect or a synergistic effect, so the use effect of the medicinal composition can be improved. The administration concentrations of glycine and metformin hydrochloride are reduced on the premise that a same treatment effect is obtained, so the generation risk of adverse reactions is reduced.

Description

[0001] technical field [0002] The invention belongs to the technical field of drugs for treating diabetes, and in particular relates to a pharmaceutical composition of glycine and metformin and its application as a drug. [0003] Background technique [0004] Diabetes is a common chronic disease, mainly due to the absolute or relative lack of insulin in the blood, which leads to high blood sugar and diabetes, and then causes fat and protein metabolism disorders. Clinically, polyuria, polydipsia, polydipsia, and polyphagia may occur. Emaciation and other manifestations, severe cases are prone to acute complications such as ketoacidosis or chronic complications such as blood vessels and nerves. Metformin hydrochloride (Metformin) is a commonly used hypoglycemic drug, which has multiple mechanisms of action, including delaying the uptake of glucose from the gastrointestinal tract, increasing peripheral glucose utilization by improving insulin sensitivity, and inhibiting l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/198A61P3/10A61K31/155
Inventor 陈琪李飞李科学杨青柏惠
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap